Subject: Specialty Quantity Limit Votrient 2217-H P2023

Drug

VOTRIENT  (pazopanib HCl)

Policy:

I.  PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.


II.  COVERED QUANTITIES 

Medication	Standard Limit	FDA-recommended dosing
Votrient (pazopanib HCl) tablet   200 mg	120 per 30 days	800 mg once daily

Place of Service:

Outpatient

The above policy is based on the following references:

1. Votrient [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2021.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

October 22, 2023